What is Oramed Pharmaceuticals Inc.'s earnings per share (EPS)?

Oramed Pharmaceuticals Inc. (ORMP) reported diluted earnings per share of $1.50 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oramed Pharmaceuticals Inc. (ORMP) Financials

ORMP

FY2025 annual

Revenue $2.0M YoY not available

Net Income $64.0M n/m YoY

EPS (Diluted) $1.50 n/m YoY

Free Cash Flow -$9.2M n/m YoY

Market Cap $171.8M as of Oct 23, 2026

Price / Sales 85.9x on $2.0M revenue, FY2025

Price / Earnings 2.7x on $64.0M net income, FY2025

Price / Book 0.5x on $317.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 10, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ORMP SEC filings page.

Oramed Pharmaceuticals Inc. (ORMP) reported $2.0M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ORMP FY2025 2026-10-04

The business remains development-stage: modest revenue barely covers direct costs while research spending and cash outflows fund operations.

In FY2025, reported net income was $75K despite an operating loss of $15.1M and operating cash flow of -$9.1M. With operating cash flow also negative in FY2024, the positive bottom line reflects non-operating accounting effects rather than an operating turnaround.

FY2025 revenue was $2.0M, while cost of revenue consumed nearly all of it, leaving just $13K of gross profit. Research and development was 3.2x revenue, so reported sales are not yet funding product-development spending.

Liabilities were $31.1M against $230.9M of assets, indicating an equity-heavy balance-sheet structure rather than debt-led financing. The reported liquidity measure equaled 78.4 months of the latest annual operating outflow at FY2025 period-end.

Financial Health Signals

Financial Health Score 51/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Oramed Pharmaceuticals Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Oramed Pharmaceuticals Inc.'s reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 21/100.

Growth

Leverage

Liquidity

With a current ratio of 6.98, Oramed Pharmaceuticals Inc. holds $6.98 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 95/100.

Cash Flow

Oramed Pharmaceuticals Inc.'s reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 1/100.

Returns

Oramed Pharmaceuticals Inc. generates a 32.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 28/100. This is up from -13.0% the prior year.

Altman Z-Score Grey Zone

2.95

Oramed Pharmaceuticals Inc. scores 2.95, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $171.8M against total liabilities of $31.1M. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/6

Oramed Pharmaceuticals Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

$0.14used

For every $1 of reported earnings, Oramed Pharmaceuticals Inc. used $0.14 of operating cash (-$9.1M OCF vs $64.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$2.7M

YoYn/m

QoQn/m

Oramed Pharmaceuticals Inc.'s EBITDA was -$2.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income

$78.2M

YoY+488.2%

QoQ+104.0%

Oramed Pharmaceuticals Inc. reported $78.2M in net income in Q2 2026. This represents an increase of 488.2% from the same quarter a year earlier. Against the prior quarter it is up 104.0%.

EPS (Diluted)

$1.84

YoY+493.5%

QoQ+102.2%

5Y CAGR+72.6%

Oramed Pharmaceuticals Inc. earned $1.84 per diluted share (EPS) in Q2 2026. This represents an increase of 493.5% from the same quarter a year earlier. Against the prior quarter it is up 102.2%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$202K

YoYn/m

QoQn/m

5Y CAGRn/m

Oramed Pharmaceuticals Inc. recorded an outflow of $202K in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt

$15.2M

YoY-3.5%

QoQ+15.5%

5Y CAGR-23.3%

Oramed Pharmaceuticals Inc. held $15.2M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding

42M

YoY+1.4%

QoQ+1.6%

5Y CAGR+5.1%

Oramed Pharmaceuticals Inc. had 42M shares outstanding in Q2 2026. This represents an increase of 1.4% from the same quarter a year earlier. Against the prior quarter it is up 1.6%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

24.6%

YoY+16.0pp

QoQ+8.5pp

Oramed Pharmaceuticals Inc.'s quarterly ROE was 24.6% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 16.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.5 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

Capital Expenditures

$2K

YoY-50.0%

QoQ-60.0%

5Y CAGR0.0%

Oramed Pharmaceuticals Inc. invested $2K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 50.0% from the same quarter a year earlier. Against the prior quarter it is down 60.0%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

ORMP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ORMP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	$2.0M	N/A	$1.3M-50.4%	$2.7M0.0%	$2.7M-0.3%	$2.7M+0.3%	$2.7M+10.4%	$2.4M-0.3%	$2.5M+283.2%	$641K	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	$2.0M	N/A	N/A	N/A	N/A	N/A	$90Kn/m	-$86K-146.0%	$187K-61.8%	$490K	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$13K	N/A	N/A	N/A	N/A	N/A	$2.6M	N/A	$2.3M+1402.6%	$151K	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$6.4M+0.9%	$6.3M-29.5%	$9.0M-67.5%	$27.6M+31.7%	$21.0M+105.1%	$10.2M-24.3%	$13.5M+12.9%	$12.0M+16.5%	$10.3M+33.4%	$7.7M+61.2%	$4.8M+45.9%	$3.3M+44.2%	-$2.3M+35.2%	$1.7M+45.0%	$1.2M
SG&A Expenses	N/A	$8.7M+35.0%	$6.5M-23.4%	$8.4M-39.0%	$13.8M+132.6%	$5.9M+40.3%	$4.2M+13.7%	$3.7M-8.8%	$4.1M+48.0%	$2.8M+12.5%	$2.5M-5.8%	$2.6M-1.0%	$2.6Mn/m	-$2.0M-268.9%	$1.2M-5.7%	$1.3M
Operating Income	N/A	-$15.1Mn/m	-$12.8Mn/m	-$15.8Mn/m	-$40.6Mn/m	-$24.2Mn/m	-$11.8Mn/m	-$14.6Mn/m	-$13.5Mn/m	-$10.8Mn/m	-$10.0Mn/m	-$7.4Mn/m	-$5.9M-237.2%	$4.3Mn/m	-$2.9Mn/m	-$2.4M
EBITDA	N/A	-$15.0Mn/m	-$12.6Mn/m	-$15.6Mn/m	-$40.5Mn/m	-$24.1Mn/m	-$11.8Mn/m	-$14.6Mn/m	-$13.5Mn/m	-$10.8Mn/m	-$10.0Mn/m	-$7.4Mn/m	-$5.9M-236.9%	$4.3Mn/m	-$2.9Mn/m	-$2.4M
Interest Expense	N/A	N/A	$2.6M+26.2%	$2.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$11.3M+255.3%	$3.2M	N/A	$100K	N/A	N/A	$300K	N/A	$400K-70.0%	$1.3Mn/m	-$1K-125.0%	$4K-98.0%	$205K+127.8%	$90Kn/m	-$24K
Net Income	N/A	$64.0Mn/m	-$19.1M-474.6%	$5.1Mn/m	-$36.6Mn/m	-$23.0Mn/m	-$11.5Mn/m	-$14.4Mn/m	-$12.7Mn/m	-$10.5Mn/m	-$11.0Mn/m	-$7.2Mn/m	-$5.7M-234.6%	$4.2Mn/m	-$3.3Mn/m	-$1.6M
EPS (Basic)	N/A	$1.53n/m	-$0.48-442.9%	$0.14n/m	-$0.94-220.5%	$0.78+39.3%	$0.56-31.7%	$0.82-4.7%	$0.86+8.9%	$0.79-9.2%	$0.87+29.9%	$0.67+8.1%	$0.62+5.1%	$0.59	$0.57n/m	-$0.02
EPS (Diluted)	$4.12	$1.50n/m	-$0.48-442.9%	$0.14n/m	-$0.94-220.5%	$0.78+39.3%	$0.56-31.7%	$0.82-4.7%	$0.86+8.9%	$0.79-9.2%	$0.87+29.9%	$0.67+8.1%	$0.62+5.1%	$0.59	$0.57n/m	-$0.02
Diluted Shares (Avg)	N/A	42M+3.8%	41M+0.7%	41M+4.0%	39M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	N/A	N/A	$2.0M	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$2.0M	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$13K	N/A	N/A
R&D Expenses	N/A	$1.6M-27.7%	N/A	$1.2M-48.6%	$1.0M-28.3%	$2.2M+87.1%	N/A	$2.2M+134.3%
SG&A Expenses	$2.8M+90.1%	$2.1M-10.5%	N/A	$1.3M+50.4%	$1.5M-14.1%	$2.3M+29.4%	N/A	$847K-56.3%
Operating Income	-$2.8Mn/m	-$3.7Mn/m	N/A	-$2.4Mn/m	-$2.5Mn/m	-$4.5Mn/m	N/A	-$3.1Mn/m
EBITDA	-$2.7Mn/m	-$3.6Mn/m	N/A	-$2.4Mn/m	-$2.5Mn/m	-$4.5Mn/m	N/A	-$3.0Mn/m
Income Tax	$23.4Mn/m	$11.1M+1805.8%	N/A	$11.1M+876.3%	-$126K-107.7%	$584K	N/A	$1.1M
Net Income	$78.2M+488.2%	$38.3Mn/m	N/A	$48.4Mn/m	$13.3M+44.2%	-$7.6M-597.5%	N/A	-$19.6Mn/m
EPS (Basic)	$1.90+493.7%	$0.94n/m	$0.23n/m	$1.16n/m	$0.32+45.5%	-$0.19-575.0%	-$0.26n/m	-$0.48n/m
EPS (Diluted)	$1.84+493.5%	$0.91n/m	$0.24n/m	$1.13n/m	$0.31+40.9%	-$0.19-575.0%	-$0.26n/m	-$0.48n/m
Diluted Shares (Avg)	43M-0.3%	42M+1.8%	N/A	43M+4.6%	43M+2.4%	41M-0.8%	N/A	41M+1.1%

Not reported in any period shown, so not listed: Interest Expense.

ORMP Balance Sheet

ORMP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$230.9M+48.7%	$155.3M-29.6%	$220.6M+36.4%	$161.6M+26.3%	$128.0M+186.8%	$44.6M+28.8%	$34.7M-26.9%	$47.4M+22.4%	$38.7M-9.6%	$42.8M+62.5%	$26.4M+20.9%	$21.8M+151.8%	$8.7M+63.6%	$5.3M+22.4%	$4.3M
Current Assets	$133.3M-6.9%	$143.2M-11.9%	$162.6M+3.5%	$157.1M+64.8%	$95.3M+135.3%	$40.5M+21.6%	$33.3M+7.4%	$31.0M+52.9%	$20.3M-35.0%	$31.2M+79.8%	$17.4M-20.2%	$21.8M+151.9%	$8.6M+63.8%	$5.3M+23.2%	$4.3M
Cash & Equivalents	$45.9M-15.6%	$54.4M+501.0%	$9.1M-77.6%	$40.5M-47.6%	$77.2M+300.3%	$19.3M+479.6%	$3.3M-33.4%	$5.0M+25.9%	$4.0M+1.6%	$3.9M+21.6%	$3.2M+82.3%	$1.8M-22.4%	$2.3M-48.7%	$4.4M+192.9%	$1.5M
Short-Term Investments	$5.4M+57.4%	$3.4M-94.0%	$57.7M+1441.9%	$3.7M-36.0%	$5.9M+77.4%	$3.3M-10.9%	$3.7M-19.4%	$4.6M+60.6%	$2.9M+0.2%	$2.9M+36.7%	$2.1M+99.4%	$1.0M+9.5%	$956K+377.3%	$200K-47.9%	$385K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$88K-83.8%	$543K
Long-Term Investments	$8.4M+137.5%	$3.5M+95.0%	$1.8M-33.1%	$2.7M-59.7%	$6.7M+70.4%	$3.9M+203.3%	$1.3M-53.5%	$2.8M+29.5%	$2.2M+305.8%	$530K-43.6%	$940K+93900.0%	$1Kn/m	$0n/m	$0n/m	$0
Total Liabilities	$31.1M+245.3%	$9.0M-84.1%	$56.7M+477.1%	$9.8M-19.6%	$12.2M+4.0%	$11.8M-23.0%	$15.3M-6.2%	$16.3M-16.4%	$19.5M+17.0%	$16.6M+990.4%	$1.5M+51.2%	$1.0M+90.7%	$529K-65.1%	$1.5M+152.0%	$602K
Current Liabilities	$19.1M+235.7%	$5.7M-89.3%	$53.2M+826.1%	$5.7M-14.0%	$6.7M+47.2%	$4.5M-14.5%	$5.3M+16.6%	$4.6M-11.8%	$5.2M+42.6%	$3.6M+143.2%	$1.5M+53.0%	$973K+95.4%	$498K-22.7%	$644K+46.0%	$441K
Non-Current Liabilities	$12.0M+183.4%	$4.2M-4.5%	$4.4M-6.2%	$4.7M-1.3%	$4.8M-33.5%	$7.2M-27.5%	$10.0M-15.1%	$11.7M-18.0%	$14.3M+9.9%	$13.0M+35086.5%	$37K+2.8%	$36K+16.1%	$31K-96.4%	$872K+442.8%	$161K
Long-Term Debt	N/A	N/A	N/A	$25K-99.8%	$12.5M	N/A	$9.7M-15.2%	$11.4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$199.7M+36.6%	$146.3M-10.7%	$163.8M+7.9%	$151.8M+31.1%	$115.8M+252.1%	$32.9M+69.5%	$19.4M-37.7%	$31.1M+61.7%	$19.2M-26.5%	$26.2M+5.5%	$24.8M+19.4%	$20.8M+155.7%	$8.1M+115.2%	$3.8M+1.5%	$3.7M
Retained Earnings	-$123.4Mn/m	-$176.6Mn/m	-$157.6Mn/m	-$163.1Mn/m	-$114.9Mn/m	-$92.6Mn/m	-$81.1Mn/m	-$69.2Mn/m	-$56.5Mn/m	-$46.0Mn/m	-$35.1Mn/m	-$27.8Mn/m	-$22.1Mn/m	-$17.9Mn/m	-$14.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$369.6M+128.6%	$268.8M+82.2%	$230.9M+48.7%	$220.5M+33.6%	$161.7M-12.2%	$147.5M-27.6%	$155.3M-29.6%	$165.1M-28.5%
Current Assets	$53.4M-46.1%	$68.2M-48.2%	$133.3M-6.9%	$136.1M-4.7%	$99.0M-35.4%	$131.5M-25.8%	$143.2M-11.9%	$142.8M-18.7%
Cash & Equivalents	$15.2M-3.5%	$13.2M-82.3%	$45.9M-15.6%	$52.2M+23.9%	$15.8M-81.4%	$74.5M+301.1%	$54.4M+501.0%	$42.1M+670.0%
Short-Term Investments	$846K-51.7%	$5.0M+34.4%	$5.4M+57.4%	$5.0M-91.4%	$1.8M-97.4%	$3.7M-95.2%	$3.4M-94.0%	$57.5M+116175.1%
Long-Term Investments	$21.9M	$18.0M+409.8%	$8.4M+137.5%	N/A	N/A	$3.5M+73.9%	$3.5M+95.0%	$646K-74.5%
Total Liabilities	$52.2M+629.1%	$30.6M+354.5%	$31.1M+245.3%	$17.2M+99.2%	$7.2M0.0%	$6.7M-81.8%	$9.0M-84.1%	$8.6M-89.4%
Current Liabilities	$10.7M+190.6%	$10.6M+92.3%	$19.1M+235.7%	$6.1M+16.0%	$3.7M-1.1%	$5.5M-83.6%	$5.7M-89.3%	$5.3M-93.3%
Non-Current Liabilities	$41.4M+840.1%	$20.0M+829.3%	$12.0M+183.4%	$12.0M+181.0%	$4.4M+1.7%	$2.2M-50.8%	$4.2M-4.5%	$4.3M-4.5%
Total Equity	$317.5M+105.4%	$238.3M+69.2%	$199.7M+36.6%	$203.3M+29.9%	$154.5M-12.7%	$140.8M-15.5%	$146.3M-10.7%	$156.4M+4.9%
Retained Earnings	-$7.0Mn/m	-$85.1Mn/m	-$123.4Mn/m	-$122.6Mn/m	-$171.0Mn/m	-$184.3Mn/m	-$176.6Mn/m	-$166.4Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ORMP Cash Flow Statement

ORMP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$5.2M	-$9.1Mn/m	-$8.4Mn/m	-$10.3Mn/m	-$27.9Mn/m	-$21.2Mn/m	-$12.4Mn/m	-$12.9Mn/m	-$14.7Mn/m	-$5.8M-225.3%	$4.7Mn/m	-$4.9Mn/m	-$4.1Mn/m	-$3.4Mn/m	-$2.3Mn/m	-$1.7M
Depreciation & Amortization	N/A	$121K-37.3%	$193K-1.5%	$196K+237.9%	$58K-24.7%	$77K+1000.0%	$7K-12.5%	$8K+33.3%	$6K+20.0%	$5K+25.0%	$4K0.0%	$4K-33.3%	$6K+20.0%	$5K-66.7%	$15K-47.0%	$28K
Stock-Based Compensation	N/A	$6.0M+47.8%	$4.1M-3.8%	$4.2M-63.4%	$11.5M+327.1%	$2.7M+479.6%	$465K-42.5%	$808K-47.8%	$1.5M-1.8%	$1.6M+148.4%	$634K-52.9%	$1.3M-8.2%	$1.5M+104.2%	$719K+165.3%	$271K-48.8%	$529K
Capital Expenditures	$9K	$9K-50.0%	$18K-92.9%	$254K-48.8%	$496K+32.3%	$375K+357.3%	$82K+446.7%	$15K+200.0%	$5K-28.6%	$7K-22.2%	$9K+800.0%	$1K-92.9%	$14K+133.3%	$6K+200.0%	$2K-8.3%	$2K
Free Cash Flow	-$5.2M	-$9.2Mn/m	-$8.4Mn/m	-$10.5Mn/m	-$28.4Mn/m	-$21.6Mn/m	-$12.5Mn/m	-$13.0Mn/m	-$14.7Mn/m	-$5.8M-225.7%	$4.6Mn/m	-$4.9Mn/m	-$4.1Mn/m	-$3.4Mn/m	-$2.3Mn/m	-$1.7M
Investing Cash Flow	$21.5M	$5.4M-94.9%	$105.8Mn/m	-$73.0M-341.8%	$30.2Mn/m	-$23.8M-613.7%	$4.6M-58.9%	$11.3Mn/m	-$7.0M-262.8%	$4.3Mn/m	-$16.0Mn/m	-$3.3Mn/m	-$13.1Mn/m	-$4.6M-358.3%	$1.8Mn/m	-$1.7M
Financing Cash Flow	-$16.7M	-$4.7Mn/m	-$52.0M-200.1%	$52.0M+382.2%	$10.8M-89.5%	$102.9M+332.6%	$23.8M	N/A	$22.7M+1328.4%	$1.6M-86.8%	$12.0M+23.9%	$9.7M-41.6%	$16.6M+185.7%	$5.8M+66.9%	$3.5M-5.6%	$3.7M
Share Buybacks	N/A	$4.7M+90.9%	$2.5M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$200Kn/m	-$2.9Mn/m	-$466Kn/m	-$1.6Mn/m	-$3.5M-270.3%	-$3.5Mn/m	-$1.9Mn/m	-$7.1Mn/m
Depreciation & Amortization	$31K+3.3%	$30K0.0%	$30K-3.2%	$31K-40.4%	$30K-44.4%	$30K-46.4%	$31K-41.5%	$52K-3.7%
Stock-Based Compensation	N/A	$1.7M-20.7%	N/A	N/A	N/A	$2.2M+69.2%	N/A	N/A
Capital Expenditures	$2K-50.0%	$5K+66.7%	$2K-81.8%	$0-100.0%	$4Kn/m	$3K+50.0%	$11K+266.7%	$5K-84.4%
Free Cash Flow	-$202Kn/m	-$2.9Mn/m	-$468Kn/m	-$1.6Mn/m	-$3.5M-270.5%	-$3.5Mn/m	-$1.9Mn/m	-$7.1Mn/m
Investing Cash Flow	$4.3Mn/m	-$19.5M-182.5%	-$1.7M-110.9%	$38.4Mn/m	-$54.9M-158.0%	$23.6M-21.3%	$15.4M-48.6%	-$34.3Mn/m
Financing Cash Flow	-$1.9M	-$10.4M	-$4.0Mn/m	-$361Kn/m	N/A	N/A	-$1.2Mn/m	-$1.3M-101.7%
Dividends Paid	$78K	$10.4M	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$4.0M+236.0%	$361K	N/A	N/A	$1.2M	N/A

ORMP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ORMP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	0.7%	N/A	N/A	N/A	N/A	N/A	96.7%	N/A	92.4%+68.8pp	23.6%	N/A	N/A	N/A	N/A	N/A
Operating Margin	-754.4%	N/A	-1176.8%	-1502.0%	-896.2%	-433.8%	-541.3%	-552.3%	-438.6%	-1561.6%	N/A	N/A	N/A	N/A	N/A
Net Margin	3202.5%	N/A	379.7%	-1352.6%	-850.5%	-424.8%	-531.1%	-519.7%	-426.7%	-1710.5%	N/A	N/A	N/A	N/A	N/A
Return on Equity	32.1%+45.1pp	-13.0%-16.1pp	3.1%+27.2pp	-24.1%-4.2pp	-19.9%+15.2pp	-35.0%+39.0pp	-74.0%-33.1pp	-40.9%+13.6pp	-54.5%-12.6pp	-41.9%-12.7pp	-29.1%-1.7pp	-27.4%-79.4pp	52.0%+140.6pp	-88.5%-46.6pp	-41.9%
Return on Assets	27.7%+40.0pp	-12.3%-14.6pp	2.3%+24.9pp	-22.6%-4.7pp	-18.0%+7.8pp	-25.8%+15.6pp	-41.4%-14.6pp	-26.9%+0.2pp	-27.1%-1.5pp	-25.6%+1.8pp	-27.4%-1.3pp	-26.1%-75.0pp	48.9%+112.0pp	-63.2%-27.1pp	-36.1%
Current Ratio	6.98-18.2x	25.19+22.1x	3.06-24.3x	27.34+13.1x	14.27+5.3x	8.93+2.7x	6.28-0.5x	6.82+2.9x	3.93-4.7x	8.62-3.0x	11.67-10.7x	22.38+5.0x	17.36+9.2x	8.19-1.5x	9.71
Debt-to-Equity	N/A	N/A	N/A	0.00-0.1x	0.11	N/A	0.50+0.1x	0.37	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Liabilities-to-Equity	0.16+0.1x	0.06-0.3x	0.35+0.3x	0.060.0x	0.11-0.3x	0.36-0.4x	0.79+0.3x	0.52-0.5x	1.01+0.4x	0.64+0.6x	0.060.0x	0.050.0x	0.07-0.3x	0.40+0.2x	0.16
Asset Turnover	0.01	N/A	0.010.0x	0.020.0x	0.020.0x	0.060.0x	0.080.0x	0.050.0x	0.060.0x	0.01	N/A	N/A	N/A	N/A	N/A
FCF Margin	-457.7%	N/A	-787.2%	-1051.2%	-797.5%	-462.1%	-479.3%	-598.7%	-237.7%	724.8%	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	N/A	N/A	N/A	N/A	N/A	0.7%	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-225.0%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-382.1%	N/A	N/A
Return on Equity	24.6%+16.0pp	16.1%+21.5pp	N/A	23.8%+36.4pp	8.6%+3.4pp	-5.4%-6.3pp	N/A	-12.5%-10.4pp
Return on Assets	21.1%+12.9pp	14.2%+19.4pp	N/A	21.9%+33.8pp	8.2%+3.2pp	-5.2%-5.9pp	N/A	-11.9%-10.5pp
Current Ratio	4.98-21.8x	6.45-17.5x	6.98-18.2x	22.25-4.8x	26.81-14.2x	23.94+18.7x	25.19+22.1x	27.08+24.8x
Liabilities-to-Equity	0.16+0.1x	0.13+0.1x	0.16+0.1x	0.080.0x	0.050.0x	0.05-0.2x	0.06-0.3x	0.06-0.5x
Asset Turnover	N/A	N/A	N/A	N/A	N/A	0.01	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	-176.1%	N/A	N/A

Not reported in any period shown, so not listed: Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Oramed Pharmaceuticals Inc. ORMP	FY2025	$2.0M	$64.0M	N/A	$171.8M	51/100
Fortress Biotech, Inc. FBIO	FY2025	$63.3M	$6.8M	10.8%	$66.4M	28/100
Adagene Inc. ADAG	FY2025	$7.7M	-$17.6M	N/A	$163.8M	64/100
Spero Therapeutics, Inc. SPRO	FY2025	$66.8M	$8.6M	12.8%	$65.8M	41/100

Where Oramed Pharmaceuticals Inc. Ranks

Frequently Asked Questions

What is Oramed Pharmaceuticals Inc.'s annual revenue?

Oramed Pharmaceuticals Inc. (ORMP) reported $2.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Oramed Pharmaceuticals Inc. profitable?

Yes, Oramed Pharmaceuticals Inc. (ORMP) reported a net income of $64.0M in fiscal year 2025.

What is Oramed Pharmaceuticals Inc.'s EBITDA?

Oramed Pharmaceuticals Inc. (ORMP) had EBITDA of -$15.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Oramed Pharmaceuticals Inc.'s gross margin?

Oramed Pharmaceuticals Inc. (ORMP) had a gross margin of 0.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Does Oramed Pharmaceuticals Inc. pay dividends?

Yes, Oramed Pharmaceuticals Inc. (ORMP) paid $0.25 per share in dividends during fiscal year 2025.

What is Oramed Pharmaceuticals Inc.'s return on equity (ROE)?

Oramed Pharmaceuticals Inc. (ORMP) has a return on equity of 32.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Oramed Pharmaceuticals Inc.'s free cash flow?

Oramed Pharmaceuticals Inc. (ORMP) recorded an outflow of $9.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Oramed Pharmaceuticals Inc.'s operating cash flow?

Oramed Pharmaceuticals Inc. (ORMP) recorded an outflow of $9.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Oramed Pharmaceuticals Inc.'s total assets?

Oramed Pharmaceuticals Inc. (ORMP) had $230.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Oramed Pharmaceuticals Inc.'s capital expenditures?

Oramed Pharmaceuticals Inc. (ORMP) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Oramed Pharmaceuticals Inc. spend on research and development?

Oramed Pharmaceuticals Inc. (ORMP) invested $6.4M in research and development during fiscal year 2025.

Does Oramed Pharmaceuticals Inc. buy back shares?

Yes, Oramed Pharmaceuticals Inc. (ORMP) spent $4.7M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Oramed Pharmaceuticals Inc. have outstanding?

Oramed Pharmaceuticals Inc. (ORMP) had 40M shares outstanding as of fiscal year 2025.

What is Oramed Pharmaceuticals Inc.'s current ratio?

Oramed Pharmaceuticals Inc. (ORMP) had a current ratio of 6.98 as of fiscal year 2025, which is generally considered healthy.

What is Oramed Pharmaceuticals Inc.'s liabilities-to-equity ratio?

Oramed Pharmaceuticals Inc. (ORMP) had a liabilities-to-equity ratio of 0.16 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

What is Oramed Pharmaceuticals Inc.'s return on assets (ROA)?

Oramed Pharmaceuticals Inc. (ORMP) had a return on assets of 27.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Oramed Pharmaceuticals Inc.'s P/E ratio?

Oramed Pharmaceuticals Inc. (ORMP) trades at 2.7x earnings, its market capitalization divided by $64.0M net income, FY2025. The market capitalization is $171.8M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Oramed Pharmaceuticals Inc.'s price-to-sales ratio?

Oramed Pharmaceuticals Inc. (ORMP) trades at 85.9x sales, its market capitalization divided by $2.0M revenue, FY2025. The market capitalization is $171.8M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Oramed Pharmaceuticals Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Oramed Pharmaceuticals Inc. (ORMP) held $59.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.1M over that year. Dividing the one by the other, the reported balance equals about 78 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Oramed Pharmaceuticals Inc.'s Altman Z-Score?

Oramed Pharmaceuticals Inc. (ORMP) has an Altman Z-Score of 2.95, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Oramed Pharmaceuticals Inc.'s Piotroski F-Score?

Oramed Pharmaceuticals Inc. (ORMP) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Oramed Pharmaceuticals Inc.'s earnings high quality?

For every $1 of reported earnings, Oramed Pharmaceuticals Inc. (ORMP) used $0.14 of operating cash (-$9.1M OCF vs $64.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Oramed Pharmaceuticals Inc.?

Oramed Pharmaceuticals Inc. (ORMP) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.